MARGINAL ZONE LYMPHOMA(MZL)

This study tests two different drug combinations in people newly diagnosed with marginal zone lymphoma (MZL), a slow-growing blood cancer. One group gets a new targeted therapy (orelabrutinib) plus two other drugs, while the other gets standard chemo-immunotherapy. The goal is to…

This study tests a drug called orelabrutinib, taken alone or with another drug (CD20 antibody), in people with untreated marginal zone lymphoma. The goal is to see how well the treatment shrinks or controls the cancer. About 88 adults will take part, and the study is currently re…

This early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …

This study tests a new approach for people with a slow-growing lymphoma called marginal zone lymphoma (MZL). Participants first get a short course of standard chemo, then a targeted drug (Orelabrutinib) to keep the cancer under control. The goal is to see if this approach improve…

This study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …

This study tests a personalized approach to treating marginal zone lymphoma, a slow-growing blood cancer. Researchers will assign treatments based on each patient's risk level, aiming to improve how long the cancer stays under control. About 145 newly diagnosed adults who need sy…

This study tests a new drug, odronextamab, combined with lenalidomide in people whose follicular or marginal zone lymphoma has returned or stopped responding to treatment. The trial compares this new combination to the current standard treatment (rituximab plus lenalidomide). Abo…

This early-phase study tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …

This study tests a combination of three drugs (orelabrutinib, rituximab, and possibly lenalidomide) in people with untreated marginal zone lymphoma, a type of blood cancer. The goal is to see how well the treatment shrinks tumors and to check for side effects. About 50 adults wit…

This study is a registry that collects information from about 2,950 adults with certain blood cancers (like CLL, DLBCL, and others) in Germany. Researchers will track what treatments patients receive, how well they work, and how patients feel over time. No new drugs or treatments…